Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases

Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00749697

Enrollment

Registered

2008-09-09

Start date

2008-05-31

Completion date

2010-07-31

Last updated

2008-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Sites Lung Bone Nodal, Thyroid Carcinoma

Keywords

radioiodine, differentiated thyroid cancers, dosimetry, metastases

Brief summary

The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.

Detailed description

Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.

Interventions

OTHERSPECT scan

SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age above 18 * histological confirmation of the differentiated thyroid carcinoma available * WHO performance score 0-2 * metastatic sites lung and/or bone and/or nodal (radiologically measurable disease \> 1 cm) * life expectancy \> 6 months * patient has undergone total/near total thyroidectomy * no past history of sensitivity/reaction to 1311

Exclusion criteria

* non iodine concentrating tumours * received chemotherapy or radiotherapy in 6 weeks * pregnant or breast feeding patients * iodine contrast injection in last 3 months

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan	—

Secondary

Measure	Time frame
The secondary outcomes will be to assess the response at 6 months post therapy in each patient	—

Countries

United Kingdom

Contacts

Primary ContactDr Kate Newbold

kate.newbold@rmh.nhs.uk020 86613638

Backup ContactDr Prasad Dandekar

prasad.dandekar@rmh.nhs.uk020 8661 3454

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026